Make informed decisions based on intelligent insights from our Clinical Trial Outcome Database (CTOD) solutions. We offer our clients, indication specific and/or drug-specific summary level databases organized using the PK/PD, clinical efficacy and safety outcomes data from the clinical literature.

At Excelra, we integrate heterogeneous data and leverage the prior knowledge to support key decision making in the drug discovery and development process through Meta-databases.

CTOD

Landscape of disease areas with expertise:

With our CTOD Services, our clients can get intelligent insights on:

  • icon 1Go-No go Decision
  • icon 2Link / Scale Biomarker to Clinical Outcome
  • icon 3Dosing Decision
  • icon 4Relative Safety & Effectiveness
  • icon 5Competitive Intelligence
  • icon 6Benchmarking
  • icon 7HEOR & Market access
  • icon 8Regularity (Labeling)

CTOD

Salient Features

Database Model and Process: a Comprehensive and scalable data structure
  • Adaptable for multiple indications
  • Allows easy expansion to newer treatments, endpoints, and trials (from both public domain and proprietary to client)
Search protocol and Sources
  • Standard search algorithms with an optimal balance between relevancy and noise
  • Multiple data sources including journal publications, conference posters, regulatory reviews, etc.
Ease of tracking

    All clinical trial publications are listed in a separated source database and linked to unique clinical trial names

Model-friendliness

    Designed to facilitate easy dataset generation, plotting, and data exploration

Client Benefits

  • Comparative safety and efficacy analysis even in the absence of head to head comparison trials
  • Link scale biomarkers to clinical outcomes
  • Understand better the dose-response relationship for a particular drug or drug class
  • Bridge to new indications
  • Optimize the trial design and predict or improve the trial outcome
  • Develop product differentiation strategies

User Group

  • Pharma and Biotech companies
  • Regulatory bodies
  • Payer groups
  • Pharmacometricians (PK-PD modeling groups)
  • Modeling and Simulation Consultants
  • Academicians
  • Health economic outcomes research groups
  • Clinical development groups
  • Clinicians

Success Stories

  • Longitudinal Model-Based Meta-Analysis (MBMA) in Rheumatoid Arthritis
  • MBMA for Quantifying Paclitaxel Dose Response in Cancer Patients
  • Clinical Trial Simulations from a MBMA of Studies in Patients with Advanced Hepatocellular Carcinoma (HCC) Receiving Antiangiogenic Therapy
  • Effect of Weight Reduction on Haemoglobin A1c (HbA1C) in weight loss trials of Type2 Diabetes patients
Scroll To Top